PROVECTUS BIOPHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
March 28, 2024
| PROVECTUS BIOPHARMACEUTICALS, INC. | |
| By: | /s/ Dominic Rodrigues |
| Dominic Rodrigues | |
| Chief Operations Consultant (principal executive officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Heather Raines | Chief Financial Officer | March 28, 2024 |
| Heather Raines, CPA | (principal financial officer and principal accounting officer) | |
| /s/ Dominic Rodrigues | Director, Vice Chairman of the Board and Chief Operations Consultant | March 28, 2024 |
| Dominic Rodrigues | (principal executive officer) | |
| /s/ Webster Bailey | Director | March 28, 2024 |
| Webster Bailey | ||
| /s/ John W. Lacey, III, MD | Director | March 28, 2024 |
| John W. Lacey, III, MD | ||
| /s/ Ed Pershing | Director and Chairman of the Board | March 28, 2024 |
| Ed Pershing | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.